• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

计算药物设计中的加速分子动力学

Accelerated molecular dynamics in computational drug design.

作者信息

Wereszczynski Jeff, McCammon J Andrew

机构信息

Department of Chemistry and Biochemistry, Center for Theoretical Biological Physics, University of California, San Diego, La Jolla, CA, USA.

出版信息

Methods Mol Biol. 2012;819:515-24. doi: 10.1007/978-1-61779-465-0_30.

DOI:10.1007/978-1-61779-465-0_30
PMID:22183555
Abstract

The method of accelerated molecular dynamics (aMD) has been shown to increase the rate of phase-space sampling in biomolecular simulations. In this chapter, we discuss the theory behind aMD and describe the implementation of two versions: dual-boost and selective aMD. Each method has its practical advantages: dual-boost aMD is useful for increasing sampling of global conformational motions while selective aMD can improve the rate of convergence of free energy calculations. Special emphasis is placed on the use of these methods in computer-aided drug design, and the example of oseltamivir binding to neuraminidase is highlighted for both cases.

摘要

加速分子动力学(aMD)方法已被证明可提高生物分子模拟中的相空间采样速率。在本章中,我们将讨论aMD背后的理论,并描述两个版本的实现:双增强和选择性aMD。每种方法都有其实际优势:双增强aMD有助于增加全局构象运动的采样,而选择性aMD可以提高自由能计算的收敛速率。我们特别强调这些方法在计算机辅助药物设计中的应用,并以两种情况下的奥司他韦与神经氨酸酶结合为例进行说明。

相似文献

1
Accelerated molecular dynamics in computational drug design.计算药物设计中的加速分子动力学
Methods Mol Biol. 2012;819:515-24. doi: 10.1007/978-1-61779-465-0_30.
2
Computational design of novel, high-affinity neuraminidase inhibitors for H5N1 avian influenza virus.新型高亲和力神经氨酸酶抑制剂的计算设计用于 H5N1 禽流感病毒。
Eur J Med Chem. 2010 Feb;45(2):536-41. doi: 10.1016/j.ejmech.2009.10.040. Epub 2009 Oct 31.
3
Infiltration of water molecules into the oseltamivir-binding site of H274Y neuraminidase mutant causes resistance to oseltamivir.水分子渗透进入 H274Y 神经氨酸酶突变体的奥司他韦结合位点导致对奥司他韦的耐药性。
J Chem Inf Model. 2009 Dec;49(12):2735-41. doi: 10.1021/ci900348n.
4
Linear interaction energy: method and applications in drug design.线性相互作用能:药物设计中的方法与应用
Methods Mol Biol. 2012;819:305-23. doi: 10.1007/978-1-61779-465-0_20.
5
Selective binding of antiinfluenza drugs and their analogues to 'open' and 'closed' conformations of H5N1 neuraminidase.抗流感药物及其类似物与 H5N1 神经氨酸酶“开放”和“闭合”构象的选择性结合。
J Phys Chem B. 2010 Oct 14;114(40):12958-64. doi: 10.1021/jp1030224.
6
Independent-Trajectory Thermodynamic Integration: a practical guide to protein-drug binding free energy calculations using distributed computing.独立轨迹热力学积分:使用分布式计算进行蛋白质-药物结合自由能计算的实用指南。
Methods Mol Biol. 2012;819:469-86. doi: 10.1007/978-1-61779-465-0_27.
7
In silico identification of the potential drug resistance sites over 2009 influenza A (H1N1) virus neuraminidase.基于计算机预测 2009 年甲型 H1N1 流感病毒神经氨酸酶的潜在耐药位点
Mol Pharm. 2010 Jun 7;7(3):894-904. doi: 10.1021/mp100041b.
8
Enhanced Molecular Dynamics Methods Applied to Drug Design Projects.应用于药物设计项目的增强型分子动力学方法。
Methods Mol Biol. 2018;1762:403-426. doi: 10.1007/978-1-4939-7756-7_20.
9
Rational design of Tamiflu derivatives targeting at the open conformation of neuraminidase subtype 1.针对神经氨酸酶亚型1开放构象的达菲衍生物的合理设计。
J Mol Graph Model. 2009 Oct;28(3):203-19. doi: 10.1016/j.jmgm.2009.07.001. Epub 2009 Aug 4.
10
Analogue inhibitors by modifying oseltamivir based on the crystal neuraminidase structure for treating drug-resistant H5N1 virus.基于晶体神经氨酸酶结构修饰奥司他韦的类似物抑制剂用于治疗耐药H5N1病毒。
Biochem Biophys Res Commun. 2007 Oct 19;362(2):525-31. doi: 10.1016/j.bbrc.2007.08.025. Epub 2007 Aug 13.

引用本文的文献

1
An Updated Review on Developing Small Molecule Kinase Inhibitors Using Computer-Aided Drug Design Approaches.利用计算机辅助药物设计方法开发小分子激酶抑制剂的最新综述
Int J Mol Sci. 2023 Sep 11;24(18):13953. doi: 10.3390/ijms241813953.
2
Insights into the Degradation of Polymer-Drug Conjugates by an Overexpressed Enzyme in Cancer Cells.癌细胞中过表达的酶对聚合物-药物偶联物的降解作用的深入了解。
J Med Chem. 2023 Feb 23;66(4):2761-2772. doi: 10.1021/acs.jmedchem.2c01781. Epub 2023 Feb 14.
3
Mechanisms of isoform-specific residue influence on GTP-bound HRas, KRas, and NRas.
构象特异性残基对 GTP 结合 HRas、KRas 和 NRas 的影响机制。
Biophys J. 2022 Oct 4;121(19):3616-3629. doi: 10.1016/j.bpj.2022.07.005. Epub 2022 Jul 6.
4
Enhanced sampling without borders: on global biasing functions and how to reweight them.无边界增强采样:关于全局偏置函数及其重新加权方法。
Phys Chem Chem Phys. 2022 Jan 19;24(3):1225-1236. doi: 10.1039/d1cp04809k.
5
Allosteric Control of a Plant Receptor Kinase through S-Glutathionylation.通过S-谷胱甘肽化对植物受体激酶进行变构调控。
Biophys J. 2017 Dec 5;113(11):2354-2363. doi: 10.1016/j.bpj.2017.08.059.
6
A single residue substitution accounts for the significant difference in thermostability between two isoforms of human cytosolic creatine kinase.单个残基取代导致了人胞质肌酸激酶两种同工型之间热稳定性的显著差异。
Sci Rep. 2016 Feb 16;6:21191. doi: 10.1038/srep21191.
7
Considerations of Protein Subpockets in Fragment-Based Drug Design.基于片段的药物设计中蛋白质亚口袋的考量
Chem Biol Drug Des. 2016 Jan;87(1):5-20. doi: 10.1111/cbdd.12631. Epub 2015 Aug 31.
8
Elucidation of Ligand-Dependent Modulation of Disorder-Order Transitions in the Oncoprotein MDM2.阐明癌蛋白MDM2中配体依赖性的无序-有序转变调控
PLoS Comput Biol. 2015 Jun 5;11(6):e1004282. doi: 10.1371/journal.pcbi.1004282. eCollection 2015 Jun.
9
Structural insights into binding of small molecule inhibitors to Enhancer of Zeste Homolog 2.小分子抑制剂与锌指增强子同源蛋白2结合的结构见解
J Comput Aided Mol Des. 2014 Nov;28(11):1109-28. doi: 10.1007/s10822-014-9788-1. Epub 2014 Aug 20.
10
Trypsinogen activation as observed in accelerated molecular dynamics simulations.在加速分子动力学模拟中观察到的胰蛋白酶原激活。
Protein Sci. 2014 Nov;23(11):1550-8. doi: 10.1002/pro.2532. Epub 2014 Aug 23.